Presentation
Investor Presentation - Q1 FY27
- Revenue ₹924cr +15% y-y; EBITDA ₹293cr +17% y-y (margin 31.7%, +50 bps); PAT ₹253cr +24% y-y (margin 27.6%, +200 bps)
- Innovation portfolio (Oncology, Respiratory, Adult Vaccines) grew to 7% of sales, driving 25% of growth
- General medicines led by Augmentin, Ceftum, T-Bact; Pediatric vaccines maintained leadership
- EBITDA margin improved due to gross margin gains (+150 bps) offsetting higher costs
- Shingrix grew 65% with strong HCP and HCO engagement
- Focus on portfolio transformation and balance sheet optimization continues
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLAXO — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLAXO to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on GlaxoSmithKline Pharmaceuticals Limited
Important.
The summary above is generated automatically from GlaxoSmithKline Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.